RNAi News GenomeWeb News Premium Content Existing subscribers login here. New to RNAi News? For a trial subscription click here.

Nastech Confirms Change in Focus While
Alnylam Addresses Partnering Concerns

[May 15, 2008]

By Doug Macron

Although Nastech had said in an SEC filing that it would refocus on RNAi, the company’s CEO said that it would not continue developing non-RNAi programs after ongoing clinical trials are completed. Meanwhile, Alnylam’s CEO said that the firm’s track record of alliances speaks for itself.

Login | Subscribe